

Triptodur[™] (triptorelin) – New drug approval

- On June 30, 2017, <u>Arbor Pharmaceuticals announced</u> the FDA approval of <u>Triptodur (triptorelin)</u> extended-release injectable suspension for the treatment of pediatric patients ≥ 2 years of age with central precocious puberty (CPP).
- Gonadotropin-releasing hormone (GnRH)-dependent CPP is defined by pubertal development occurring before the age of 8 years in girls and 9 years in boys. CPP is a rare disease occurring in about 1 out of every 5,000 to 10,000 children and is more common in girls than boys.
- Triptorelin is the first GnRH agonist to offer once-every 6 month dosing for the treatment of CPP in the U.S.
- The efficacy and safety of Triptodur were based on a single-arm, open-label study of 44 children
 with CPP and naïve to previous GnRH treatment administered Triptodur every 24 weeks over a 12
 month period. Triptodur demonstrated a return to pre-pubertal luteinizing hormone (LH) levels in
 93% of patients, with pre-pubertal LH suppression maintained at 12 months by 98% of patients.
- Triptodur is contraindicated during pregnancy, and in individuals with a known hypersensitivity to triptorelin, any other component of the product, or other GnRH agonists or GnRH.
- Warnings and precautions of Triptodur include initial rise of gonadotropins and sex steroid levels, psychiatric events, and convulsions.
- The most common adverse reactions (≥ 4.5%) with Triptodur use were injection site reactions, menstrual (vaginal) bleeding, hot flush, headache, cough, and infections (bronchitis, gastroenteritis, influenza, nasopharyngitis, otitis externa, pharyngitis, sinusitis, and upper respiratory tract infection).
- The recommended dosage of Triptodur is 22.5 mg administered as a single intramuscular injection once every 24 weeks.
 - Triptodur must be administered under the supervision of a physician.
 - Triptodur treatment should be discontinued at the appropriate age of onset of puberty at the discretion of the physician.
 - Response to Triptodur should be monitored with LH levels after a GnRH or GnRH agonist stimulation test, basal LH, or serum concentration of sex steroid levels beginning 1 to 2 months following initiation of therapy, during therapy as necessary to confirm maintenance of efficacy, and with each subsequent dose.
 - Height should be measured every 3 to 6 months and bone age should be monitored periodically.
- Arbor Pharmaceuticals plans to launch Triptodur in the 4th quarter of 2017. Triptodur will be available as a kit containing one single dose vial of Triptodur 22.5 mg, one glass syringe prefilled with 2 mL of sterile water for injection, and two sterile 21 gauge, 1½" needles.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.